Latest News and Press Releases

Ongoing phase 1b trial is designed to evaluate safety, tolerability, and efficacy of si-544 in T-cell mediated autoimmunity Dosing of MAD stage has been initiated; first results expected for late...

-    Addressing high unmet medical need in locally advanced soft tissue sarcoma-    Targeted tumor treatment independent of specific molecular targets or tumor subtypes Munich, Germany – May 24,...

- First-in-class checkpoint inhibitor IOS-1002 (targeting LILRB1 (ILT2), LILRB2 (ILT4), KIR3DL1) being evaluated as mono and combination therapy in patients with advanced solid tumors Schlieren...

ROTTERDAM, May 12, 2023 - Pan Cancer T B.V., a biotech spin-off from Erasmus MC dedicated to the discovery and development of next-generation TCR-T therapies against solid tumors, today announces the...

Data presented at RACS 91st Annual Scientific Congress 2023Initial findings demonstrate that BellaSeno’s resorbable implants are safe, well tolerated and lead to natural tissue growth Leipzig,...

- OMN6 demonstrates safety and tolerability at clinically significant dose levels   JERUSALEM, Israel, May 8th, 2023 -- Omnix Medical, a biopharmaceutical company developing next-generation...

- Renowned immunology expert from MD Anderson Cancer Center to lead seasoned group of scientific advisors Schlieren (Zurich Area), Switzerland, and Gaithersburg, MD, USA – April 25, 2023 –...

Berlin, Germany & Zurich, Switzerland – April 12, 2023 -- ProBioGen and ImmunOs Therapeutics announce the extension of their partnership for further large-scale manufacturing of clinical material...

Presentation at the World Vaccine Congress 2023EBV-infections associated with many cancers and multiple sclerosis Munich, Germany, April 3, 2023 – EBViously, a start-up developing novel vaccines...

Eine vertiefte Analyse der vielversprechenden Top-Line-Daten für metabolische Biomarker hat ergeben, dass die Ergebnisse der BANON-Studie nicht allgemein auf HIE-Patienten in der klinischen Routine...